MET Mutations in Non-Small Cell Lung Cancer: A Case Series

Mutations in the MET proto-oncogene account for a small, but targetable, subset of non-small cell lung cancers. While a small, prospective study of 4 patients treated with the MET inhibitors crizotinib or cabozantinib reports response in patients with MET exon 14 skipping mutations, this is the biggest study in this patient population. We intend to add to this sparse body of literature by retrospectively reporting our experience with using MET inhibitors in patients with MET mutated non-small cell lung cancer.

You may be eligible for this study if you meet the following criteria:

• Conditions: TBD, tbd, tbd
• Age: 99 years or below
• Gender: All